Company intelligence / Profile preview
Purple Biotech Ltd.
Rehovot, Shfella Area, Israelpurple-biotech.com ↗
- Ownership
- Public · PPBT
- Employees
- ~9
- Development stage
- Phase 2
01
Overview
Completed Phase 2 study for CM24 in combination with anti-PD-1 and chemotherapy for pancreatic cancer showing improvement across efficacy endpoints and identification of potential biomarkers. NT219 demonstrated anti-tumor activity in combination with cetuximab in Phase 1 for head and neck cancer.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesSmall moleculesTri-specific antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
University of Colorado
04
Financials
- Market cap
- $172.6K
- Total revenue
- $0
- Enterprise value
- $-5.8M
Beyond the preview
Go deeper on Purple Biotech Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Purple Biotech Ltd..